Promising combo tackles rare sarcoma in early trial
NCT ID NCT05099666
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs, lurbinectedin and doxorubicin, in people with advanced soft-tissue sarcoma or leiomyosarcoma that cannot be cured with standard treatments. The first part finds a safe dose, and the second part compares the combination to lurbinectedin alone to see which works better at slowing cancer growth. About 62 adults with measurable disease are taking part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LEIOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02115, United States
-
Mayo Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Jacksonville
Jacksonville, Florida, 32224, United States
-
Mayo Rochester
Rochester, Minnesota, 55905, United States
-
Memorial Sloan Kettering
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Patient's own immune cells fight advanced sarcoma?
- Can an immune-boosting drug make chemotherapy more effective against sarcoma?
- Immunotherapy boosts chemo against rare sarcomas?
- New mRNA shot targets Hard-to-Treat cancers in early human test
- New hope for sarcoma patients: drug slows tumor growth in late-stage trial
- Cancer drug shows promise in keeping sarcoma in check